Novartis
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA International
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA Breaking News
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA International
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA Breaking News
"Hospitals are very significant polluters, despite the great benefits that we all enjoy when we fall sick," says Novartis President. By 2050, 70% of the world's population is expected to live in cities - that equates to 2.5 billion more than today. By then, the global temperature is likely to be at least 1.5 degrees Celsius warmer, with some sources suggesting it could be 3 degrees, depending on how drastically the world reacts. Rising temperatures cause additional stress to the human body, but that's not the only risk to our health. As the healthcare and pharmaceutical industries battle to st...
Euronews (English)
Swiss pharma major Novartis on Wednesday updated its mid-term guidance as it reported a fourth-quarter net income of $8.48 billion, up from last year's $1.47 billion. Earnings per share were $4.14, significantly higher than $0.69 a year ago. Looking ahead for fiscal 2024, the company projects net sales to grow mid single digit and core operating income to grow high single digit. Further, the company updated mid-term guidance, with net sales expecting to grow 5% cc CAGR 2023-2028 with core operating income margin expanding to around 40% by 2027. The latest results included net income from disco...
DPA
Swiss pharma major Novartis on Wednesday updated its mid-term guidance as it reported a fourth-quarter net income of $8.48 billion, up from last year's $1.47 billion. Earnings per share were $4.14, significantly higher than $0.69 a year ago. Looking ahead for fiscal 2024, the company projects net sales to grow mid single digit and core operating income to grow high single digit. Further, the company updated mid-term guidance, with net sales expecting to grow 5% cc CAGR 2023-2028 with core operating income margin expanding to around 40% by 2027. The latest results included net income from disco...
DPA International
Swiss pharma major Novartis on Wednesday updated its mid-term guidance as it reported a fourth-quarter net income of $8.48 billion, up from last year's $1.47 billion. Earnings per share were $4.14, significantly higher than $0.69 a year ago. Looking ahead for fiscal 2024, the company projects net sales to grow mid single digit and core operating income to grow high single digit. Further, the company updated mid-term guidance, with net sales expecting to grow 5% cc CAGR 2023-2028 with core operating income margin expanding to around 40% by 2027. The latest results included net income from disco...
DPA Breaking News
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら